Research and Development in Biotechnology (Except Nanobiotechnology)

What the Biotech R&D (ex. Nano)–FY2026 join is

NAICS 541714 and fiscal year 2026 meet here. $243,697,582.31 is the USAspending.gov obligation sum on the yearlyTrend row that carries both tags. It is not Research And Development In Biotechnology (Except Nanobiotechnology)'s nationwide all-year total of $19,013,172,722.03, not every federal dollar coded to FY2026, and not an outlay register. The packet does not split therapeutic areas, and it excludes nanobiotechnology by NAICS definition. 2,378 is an industry-extract action count: modifications and repeat awards add rows across years. Unique recipients are unpublished. This cell is not a lab census, a named-sponsor roster, or a trial-protocol catalog.

Open /industries/541714/ (NAICS 541714) for the industry table without this FY2026 filter, /fiscal-years/2026/ (FY2026 federal spending) for the year table without this NAICS filter, /industries/ (All industries) for every industry, and /ties/ (All spending ties) for the rest of the join list. Quote those hubs as parents, not as addends to $243,697,582.31. Biotech R&D is not residual scientific consulting (541690). Research codes and consulting codes stay separate.

FY2026 beside the Biotech R&D (ex. Nano) longer book

USAspending labels NAICS 541714 as Research And Development In Biotechnology (Except Nanobiotechnology). That code produced $243,697,582.31 when crossed with fiscal year 2026. The industry-wide 541714 hub does not require a FY2026 filter. The year hub does not require Biotech R&D (ex. Nano). Only this tie applies both filters. The packet does not split therapeutic areas, and it excludes nanobiotechnology by NAICS definition. Do not forecast the rest of FY2026 from this snapshot. The packet has no remaining-year estimate.

Correlation is not causation: FY2026 did not cause $243,697,582.31 by existing as a large or small budget year. The join is 541714 × FY2026 only. This cell is not a lab census, a named-sponsor roster, or a trial-protocol catalog. Do not invent contractors or award recipients to fill the gap. Campaign donations on FEC tables do not fund this USAspending cell; the datasets are separate. Two thousand three hundred seventy-eight industry-extract awards describe 541714 across years, not a FY2026 lab or trial census.

Questions

How much Biotech R&D (ex. Nano) spending is obligated in FY2026?

USAspending.gov lists $243,697,582.31 in Research And Development In Biotechnology (Except Nanobiotechnology) (NAICS 541714) obligations for FY2026. That yearlyTrend amount is 1.3% of the industry's $19,013,172,722.03 extract-wide total. It is an obligation join, not an outlay and not every federal dollar in FY2026. Unique recipients are unpublished.

Is $243,697,582.31 the entire Biotech R&D (ex. Nano) USAspending total?

No. NAICS 541714's extract-wide total is $19,013,172,722.03. FY2026 is 1.3% of that book. Other fiscal-year rows for the same industry are separate cells. Do not add /industries/541714/ into this join. 2,378 award records stay on the industry extract, not on this yearlyTrend row.

Is $243,697,582.31 cash already paid in FY2026?

No. Obligations are commitments recorded on USAspending.gov awards. Outlays — money that actually left the Treasury — are a different concept and are not this packet's headline. Treating $243,697,582.31 as checks already cleared in FY2026 confuses those terms. Prefer the live industry and year hubs if the tables moved.

Where is the live Biotech R&D (ex. Nano)–FY2026 table?

/industries/541714/ is the industry parent and /fiscal-years/2026/ is the year parent. /industries/ covers every industry without the NAICS×year intersection as the headline. /ties/ lists other pairs. Those hubs are not addends. Keep both sides of the join when citing $243,697,582.31.